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Abstract
Background: Recent years have seen publication of a considerable number of clinical trials of
preventive interventions against clinical malaria in children. There has been variability in the
specification of end-points, case definitions, analysis methods and reporting and the relative lack of
standardization complicates the ability to make comparative evaluations between trials.
Methods: To prepare for a WHO consultation on design issues in malaria vaccine trials, controlled
trials of preventive interventions against malaria in children in endemic countries were identified in
which clinical malaria, or death, had been one of the main end-points. Trials were included that
evaluated the impact of vaccines, insecticide-treated bed nets (ITN), intermittent presumptive or
preventive therapy in infants (IPTi) or, in one instance, vitamin A supplementation. Methods that
had been used in these trials were summarized and compared in order to identify issues that were
directly relevant to the design of malaria vaccine trials.
Results: 29 controlled trials of preventive malaria interventions were identified, of which eight
were vaccine trials. Vaccine trials that were designed to detect an effect on clinical malaria all
reported the incidence rate of first episodes of clinical malaria as their primary endpoint. Only one
trial of a preventive intervention (of ITN) was identified that was designed to detect an effect on
severe malaria. A group of larger trials were designed to detect an effect of impregnated bed nets
or curtains on all-cause mortality as the primary end-point. Key methodological and reporting
differences between trials are noted in the text. Two issues have been identified that are of some
concern. Firstly, the choice of primary endpoint is not stated in the reports of a number of the trials
and, secondly, the relationship between pre-specified analysis plans and trial reports is rarely made
clear.
Conclusion: This article reports an investigation into the ways in which trial design and reporting
could be improved and standardized to enable comparative evaluation of the relative merits of
malaria control measures, and specifically with respect to the design of malaria vaccine trials. The
need for standardization of clinical trial design, conduct, analysis and reporting has been also
affirmed as a priority area by the Malaria Vaccine Technology Roadmap.
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Background
The development and deployment of new and improved
intervention methods for malaria control shows promis-
ing signs of reducing significantly the global burden of
malaria. However, the search for more effective control
methods still has very high priority. Controlled trials
remain essential for the rigorous assessment of the poten-
tial impact of new tools and strategies to reduce morbidity
and mortality caused by malaria. In recent years, there
have been a considerable number of randomized control-
led trials of new malaria interventions directed at chil-
dren, including trials evaluating candidate malaria
vaccines, insecticide-treated bed nets (ITN) and intermit-
tent presumptive or preventive therapy in infants (IPTi).
The appropriate choices of the primary end-points in such
trials and the measurement methods are prerequisites for
the proper evaluation of the interventions. The end-points
and measurement methods must allow comparability of
the performance of the same intervention in different
locations and age groups and over time at the same loca-
tion. In addition, the comparability of performance of
alternate control measures, or combinations of measures,
relies on standardized methods of assessment.
To prepare for a World Health Organization (WHO) con-
sultation on design issues in malaria vaccine trials, the
methods that have been used in reported malaria preven-
tive intervention trials to estimate efficacy against clinical
malaria and related end-points were reviewed and the
strengths and weaknesses of the different approaches were
summarized. The aim is to provide a resource for those
planning clinical trials of preventive malaria interven-
tions. The target audience is clinical trialists, statisticians
and other technical personnel. A companion paper,
resulting from a WHO consultation on the issues, was
directed at policy makers, funders and regulators [1].
Methods
Identification of studies
Reports of trials published between 1990 and 2007 evalu-
ating the impact of preventive malaria interventions were
identified (specifically vaccines, impregnated bed nets
and IPTi). Trial reports were found primarily through
PubMed database searches. Papers were sought using the
following search terms: malaria vaccin*, malaria vaccines
[MeSH], (malaria or insecticide-treated or impregnated or
pyreth* or deltamethr*) and (bednet or bed net or mos-
quito net or curtain), malaria ipti, malaria intermittent
therapy infants, malaria presumptive therapy infants,
malaria preventive therapy infants, malaria preventive
clinical trial. Further trials were identified through the ref-
erences of retrieved articles. In addition, investigators
responsible for the design and analysis of clinical trials of
preventive interventions against malaria were interviewed
as part of a WHO consultation process on design of phase
3 trials of malaria vaccines. Each interviewee was asked to
identify further eligible studies. Data on trial methods and
reporting for each study were extracted into tables and are
summarized [see additional file 1].
Eligibility criteria
Papers were included if they reported randomized con-
trolled trials of preventive malaria interventions with a
primary or secondary objective stated as the estimation of
efficacy against clinical malaria, severe malaria or all-
cause mortality. Trials were excluded, to coincide with the
intended scope of the review, if they were conducted in
adult populations or in areas of unstable malaria trans-
mission (i.e. annual entomological inoculation rate < 1 or
little evidence of acquisition of clinical immunity in the
population) or they did not report incidence end-points.
Results
29 randomized clinical trials of malaria preventive inter-
ventions in children published between 1990 and 2007
were identified, which reported estimation of efficacy
against clinical malaria, severe malaria or all-cause mor-
tality. Six trials, all of insecticide-treated bed nets or cur-
tains, were cluster randomized. The other 23 were
individually randomized.
Choice of the primary end-point
The trials could be classified broadly into two groups. The
largest group consisted of trials designed primarily to
detect an effect on clinical malaria. In some of these both
clinical malaria and anaemia are described as efficacy
measures in the same trial. In several trials, it was not pos-
sible to identify whether a single primary end-point had
been specified amongst several end-points that were
ostensibly reported as "co-primaries".
The other group of trials, all of ITNs, were those designed
to detect an effect on all-cause mortality. Severe malaria
was a primary outcome measure in only one trial [2].
Clinical malaria as a primary end-point
All malaria vaccine trials [3-8] and several trials of IPTi [9-
15], whose stated main objective was the estimation of
efficacy against clinical malaria, had as their primary end-
point the incidence rate of the first episode of malaria
(time to first or only episode of malaria). For this end-
point, following entry into the trial, only the first episode
of clinical malaria for each child contributes towards the
calculation of the malaria incidence rate. Episodes of the
disease after the first are ignored. Each child contributes a
variable amount of time at risk to the denominator for the
rate calculation, from the beginning of the efficacy follow-
up period (i.e. from first vaccination for "intention to
treat" analyses and generally 14 days from final vaccina-
tion for "according to protocol" analyses) until the onset
Malaria Journal 2009, 8:23 http://www.malariajournal.com/content/8/1/23
Page 3 of 8
(page number not for citation purposes)
of the first episode of malaria or the end of the follow-up
period (whichever is the shorter). The point estimate of
efficacy is calculated as 1-(incidence rate ratio) or by using
Cox proportional hazards regression models or Poisson
regression models, if adjustment for other factors is neces-
sary. The use of such "time-to-first-event analyses" has
been common in evaluating preventive interventions
against malaria, unlike in some studies of other infectious
diseases [16-19]. Methods such as these that allow varia-
ble follow-up time between individuals to be taken into
account are generally accepted to be preferable for field
efficacy trials. A simple comparison of the ratio of propor-
tions infected remains the method of choice for artificial
challenge trials; here equal follow-up time for each indi-
vidual is a reasonable assumption. However, the utility of
"time-to-first-event analyses" for public health policy-
makers has been questioned as it is argued that it does not
measure the overall burden of malaria, which includes
second and subsequent episodes in the same individual.
An alternative end-point for trials designed to examine the
overall impact against clinical malaria is the rate of all epi-
sodes of malaria. Only one trial was identified reporting
multiple episodes of malaria as its primary end-point
[20]. For this end-point, the total number of malaria epi-
sodes are counted, including multiple episodes in the
same child, using a rule for the minimum number of days
between episodes to distinguish a "new" episode from a
continuation of the previous one (usually 28 days but
dependent on the chemotherapy used). In some trials
molecular markers have also been used to distinguish
recurrences from new infections. This end-point may be of
more relevance to public health than one based upon the
first or only episode of clinical malaria. However, the
analysis of data including multiple episodes in the same
child is not straightforward as multiple episodes are not
independent events. That is, once a child has had one epi-
sode, the child is more likely to have another episode, for
a variety of reasons, than a child who has never had an
episode. Thus, attacks of malaria tend to "cluster" within
individuals. Complex models are needed to analyse these
sorts of data, on which there is still not a consensus and
on which further methodological research is required. To
date, unease about this issue seems to have inhibited the
use of this as a primary end-point in most trials. A recent
WHO consultation highlighted the need for an explana-
tory document, outlining the merits and disadvantages of
the different approaches to measurement of efficacy
against clinical malaria in preventive intervention tri-
als[21]. Drafting of such a document is underway.
What is clinical malaria?
Defining what constitutes an episode of clinical malaria is
not straightforward in areas in which the disease is highly
endemic. In such areas, at any one time, a significant pro-
portion of children in a community may have malaria
parasites in their blood. Many will be asymptomatic and
others will have symptoms consistent with malaria. In
some of this latter group the symptoms may be directly
attributable to malaria but, because malaria symptoms are
not specific to the illness, in others the symptoms may be
due to another condition and the malaria parasites in
their blood are merely coincidental. In general, the higher
the blood parasite load, the more likely it is that the symp-
toms are due to malaria. Thus, in preventive trials, it is
common practice to define clinical malaria as being
present in those who have symptoms and signs consistent
with malaria and who also have a density of parasites in
their blood greater than some specified level. Choice of
the appropriate minimal parasite density level (cut-off)
for defining malaria will depend upon the endemicity of
malaria in the study area. For example, in areas where
malaria is relatively uncommon, the finding of any
malaria parasites in the blood of someone presenting to a
health facility with fever provides a sensitive and specific
diagnosis of the disease. For malaria endemic areas, Smith
et al [22] devised a method for calculating the sensitivities,
specificities and malaria attributable fraction of different
parasite density cut-offs, using baseline data on the preva-
lence of different levels of parasite density measured in
children in the community not presenting with malaria
symptoms. To choose the appropriate cut-off level in a
specific intervention trial, it is important that the data
used for deriving this level are from the same epidemio-
logical setting as the intervention trial (including age,
transmission intensity, health care facilities and interac-
tion with study staff). This is often not specified in the
reports of trials.
In recent malaria vaccine trials in children, efficacy esti-
mates using different parasite density cut-offs, in the same
trial, have been presented. Case definitions with lower
specificity (lower parasite cut-off levels) should theoreti-
cally yield lower point estimates of efficacy. Curiously,
this expected effect has not been seen generally in the tri-
als reviewed. Further research into this issue is warranted.
Also, it would aid interpretation if the sensitivities and
specificities of the various case definitions and parasite
density cut-offs used, as derived by the Smith et al
method, were presented in publications of intervention
trials. This has generally not been done.
A different approach to defining clinical malaria was used
in an ITN trial performed in Côte d'Ivoire [23]. In this
trial, each participant was regularly tested for the level of
malaria parasites in their blood. Each child was then
assigned a probability of having suffered an episode of
clinical malaria in a given period, according to the highest
parasite density recorded during that period, the probabil-
ity being determined using a logistic regression approach.
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The sum of the probabilities across individuals was taken
as the total "episodes" of malaria in the group. For analy-
sis purposes, only one episode was included within any
six-week period. While this approach does not go as far as
avoiding any estimation of incidence of malaria at the
individual level (as has been proposed as a possibil-
ity[24,25]), this study does move away from classifying
outcomes in an individual child in a simple binary way.
Another measure of clinical malaria was used in a trial of
intermittent preventive therapy with sulphadoxine/
pyrimethamine (SP) and iron supplementation per-
formed in Kenya[26]. The analysis was based on the risk
rather than the rate of malaria. Thus, the number of cases
of malaria was divided by the number of children at risk
rather than by the person-time at risk.
Use of pre-treatment
In trials of malaria vaccines, an assessment has commonly
been made of the effect of the vaccine on the incidence of
parasitaemia as well as on clinical malaria. The former has
been measured by taking repeated blood smears from
some children following vaccination. In order to be able
to measure new infections, in most trials, anti-malarial
treatment has been given prior to vaccination to clear
asexual parasitaemia. Thus, in five out of eight malaria
vaccine efficacy trials in children, participants were treated
for malaria at the start of the trial. A sixth trial used amo-
diaquine/SP pre-treatment in a separate cohort, where
only anti-infection efficacy data was generated[7]. In one
trial, there was a double randomization (by vaccine vs
control and pre-treatment vs no pre-treatment) to exam-
ine the impact of pre-treatment on vaccine efficacy[27].
Although the numbers were small in this study, and the
primary end-point was parasite density, there was a
marked "sterilizing" effect of SP pre-treatment for several
weeks into the follow-up period, such that efficacy could
not be determined in the pre-treatment group. Epidemio-
logical studies in Kisumu (unpublished) and Mali[28]
have been conducted in children to estimate the duration
of effect of artemether/lumefantrine and SP, respectively,
on time to clinical malaria. In the latter study, SP pre-treat-
ment delayed the median time to first clinical episode
from 38 days to 68 days. The data now available suggest
that pre-treatment of vaccine trial participants may have
complex effects of unpredictable duration on observed
vaccine efficacy. Thus, it may be appropriate to restrict
pre-treatment to trials where time to infection is the pri-
mary end-point. Where pre-treatment is used, it may be a
major complicating factor for interpretation of morbidity
end-points.
Surveillance methods
All malaria vaccine trials in children published to date
have included some form of active case detection (ACD)
for at least some trial participants. Two trials [3,7] used
active surveillance in one group and passive case detection
(PCD) only in other group(s) in the same study. In one of
the study cohorts in the study of Alonso et al [7] the sched-
uled interaction between study staff and participants dur-
ing the efficacy follow-up period was less than for any
other cohort in the vaccine studies identified. Participants
were visited at home once a month to establish presence
in the study area and to record any unreported serious
adverse events but the visits did not involve malaria mor-
bidity surveillance. Clinical malaria episodes, identified
only by children presenting at a clinic, are therefore likely
to have been more severe, on average, than those experi-
enced in other vaccine trials in which active case detection
was employed. The clinical malaria cases identified in this
study are likely to accord more closely to those encoun-
tered in normal health practice in the study area and,
therefore, it might be argued that the trial results will be
more relevant to public health.
The criteria used to trigger the taking of a blood smear to
assess for a possible clinical malaria episode varied from
trial to trial. This also affects interpretation of efficacy
results. Thus, the results of trials must be interpreted in the
light of the case detection systems used.
In some trials, both ACD and PCD were used to detect
clinical malaria cases and efficacy results were reported for
cases detected by each of these methods[3]. With such
dual surveillance the severity of the clinical malaria
detected by PCD is likely to be less severe, on average,
than if there had been no ACD. In trials where the choice
of the end-point is designed to approximate what might
happen in the usual health care system the use of ACD
should be avoided. Monthly visits to trial participants for
purely safety information would appear to be an appro-
priate level of interaction for studies planning PCD only
surveillance.
Blood smear methods
There are three methods for calculating parasite density
that have been employed in published intervention trials.
Firstly, reading 100 or 200 high power fields, with the
assumption that the volume of each high power field is 1/
500 μl. Secondly, an assumption that the total white cell
count is 8,000/μl and reading to 200 white blood cells.
Thirdly, a calculation of white cell count individually and
then reading to 200 WBC, with adjustment using the cal-
culated count. It is difficult to compare the results of stud-
ies in which different counting methods have been used.
Standardization on one method is desirable for accuracy,
precision and to aid comparisons of the results in different
trials and is essential for a multi-site licensure trial. Dou-
ble reading of all blood smears for efficacy end-points is
also undertaken, and is highly desirable, in most interven-
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tion trials. The elements of slide taking and reading that
require standardization include: staining of blood smears
including where Field's stain and Giemsa stain are used;
procedure for double and third reading of smears; internal
quality control (QC) procedures; external QC of a propor-
tion of blood smears and the process for resolution of dis-
crepancies found through external QC.
Other end-points
While clinical malaria has been the primary end-point in
most studies of preventive interventions studies, some
studies have measured the impact on more severe disease
or death and others have evaluated the impact on hospital
utilization for any cause.
Severe malaria, malaria-related mortality and all-cause mortality
Whilst the presenting features and, to some extent, predic-
tors of mortality in hospitalized cases of malaria have
been adequately described in a handful of settings in sub-
Saharan Africa [29-40], only a single published preventive
intervention trial included severe malaria as the primary
end-point[2], though other trials have had this as a sec-
ondary end-point. Identifying deaths due to malaria is
problematic in situations where post-mortem is uncom-
mon and many children may die out of a hospital setting.
There is a well established precedent for the use of verbal
autopsies to assign causes of death in both sub-Saharan
Africa[41] and Asia[42], but there is limited experience of
using these methods to assess the impact of a preventative
intervention on malaria-related mortality[43] and the
sensitivity and specificity of the assignment of a malaria
death is poor. However, with a good surveillance system
all deaths from any cause can be identified with consider-
able reliability. Thus, in some trials, specifically some of
the ITN trials [2,43-46], death from any cause has been
the primary end-point. Whilst not appropriate for a licen-
sure trial, the impact of a vaccine on this end-point may
be important for assessing the public health impact of a
malaria vaccine post-licensure, and might be a focus for
Phase 4 studies. In some settings, an effect on severe
malaria may also be ascertainable in a study in which all-
cause mortality is the primary end-point[2].
Hospital admissions
In some trials an attempt has been made to estimate the
extent to which a preventive malaria intervention has
reduced the overall burden of illness on the health service,
such as the impact on all-cause clinic or hospital attend-
ance. For example, this measure was included in the eval-
uation of the Asembo/Gem Kenyan ITN trial [47]. Over
20,000 clinic attendances were included in the primary
analysis and a statistically significant efficacy of 27%
against all-cause clinic attendance was reported. No sam-
ple size calculation was provided, but it appears likely that
such large numbers are necessary to provide adequate
power to detect such an effect. This end-point, though
potentially difficult to measure in some circumstances,
would be highly informative for those making implemen-
tation decisions in malaria control, as it provides a general
measure of the potential saving to the health service.
Use of multiple efficacy endpoints
A relatively large number of possible efficacy end-points
are potentially available to malaria investigators and
malaria preventive intervention trials may be particularly
vulnerable to the multiple comparisons problems in trial
design. Many of the trials reviewed reported a large
number of different efficacy end-points (more than 20 in
some trials). Furthermore, it is not generally made clear in
papers how many efficacy end-points were analysed but
were not reported. A ranking of end-points pre-unblind-
ing, in the analytic plan, with publication in the pre-spec-
ified rank order would be one way to address concerns
about multiple comparisons. Conservative methods such
as adjusting significance levels for the number of end-
points examined have not been used in trials reported to
date. In practice, in addition to the primary end-point (if
one is specified!) the sum of the evidence from all of the
end-points measured is usually taken into account,
together with their biological plausibility and their con-
sistency, in the overall assessment of the potential impact
of an intervention. Assessment would be aided if, for all
trials, the reporting and analysis plans were made availa-
ble for review together with the trial protocol.
Conclusion
There is a wealth of data available from randomized con-
trolled trials of malaria preventive interventions directed
at children, much published in recent years. Further infor-
mation will become available through ongoing iPTi trials
and the planned large multi-site phase 3 trial of the Glax-
oSmithKline/Malaria Vaccine Initiative vaccine candidate
RTS, S. Attention to the design issues identified above will
aid the generation of data that can inform public health
decisions.
It is notable that many of the trials identified in this
review report the incidence rate of first episodes of clinical
malaria as the primary endpoint. Given the public health
interest in a potential new intervention's impact on the
community burden of clinical malaria, further attention
to analysis methods for the incidence rate of all episodes
of malaria appears to be one priority for those undertak-
ing clinical trials in this field. This may help bridge the gap
between proof-of-concept and evaluation of public health
benefit for preventive interventions against clinical
malaria.
An ambitious, but highly laudable goal, stated as a prior-
ity area in the strategic framework of the Malaria Vaccine
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Technology Roadmap[48], is clinical trial standardiza-
tion. The hope is that those engaged in preventive inter-
vention trials against malaria, and especially those
engaged in vaccine trials, will discuss and come to agree-
ment on optimal trial design, analysis method and report-
ing requirements. Having agreed these aspects the plan is
to produce standardized clinical trial methods, protocols
and reporting templates. This report forms one part of the
background to such harmonization and standardization
efforts. The Initiative for Vaccine Research, World Health
Organization is engaged in ongoing activities to facilitate
norms, standards and best practice in this area[21].
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